MedTrace Logo

Control of Pain in Intravitreal Injections Using Topical NSAIDs

NCT04343222 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2023-06-12

Study results available
· View outcomes & findings →

Summary

Intravitreal injections (IVI) are a common form of treatment for multiple retinal pathologies. The investigators hypothesize that an intervention with a topical NSAID will alleviate pain experienced at intravitreal injection (IVI) and post-IVI. 46 participants will be recruited, randomized into 1 of 3 treatment arms, and can expect to be on study for a day.

Conditions

  • Intravitreal Injections
  • IVI

Interventions

DRUG

Bromfenac

An NSAID used to treat eye pain and swelling

DRUG

Artificial tears

eye drops to lubricate the eye and maintain moisture

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Mihai Mititelu, MD, MPH · University of Wisconsin, Madison

  • Maxwell Wingelaar, MD · University of Wisconsin, Madison

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-27
Primary Completion
2019-12-19
Completion
2019-12-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343222 on ClinicalTrials.gov